期刊文献+

类风湿关节炎治疗药物研究进展 被引量:8

Advances of Pharmaceuticals against rheumatoid arthritis
下载PDF
导出
摘要 类风湿关节炎是慢性自体免疫性疾病,临床用TNF-α阻滞剂、白介素-1受体阻滞剂和嘧啶合成抑制剂等药物治疗取得较好的疗效。论述了一些近年来治疗类风湿关节炎的新药,这些药物在短期和中期治疗中较为安全和有效,但长期治疗的疗效和毒性仍有待于进一步研究。 Rheumatoid arthritis is a chronic inflammatory autoimmune disease. Recent advances have led to the successful use of therapies that target TNF-α, interleukin-1 and inhibition of pyrimidine synthesis. This presentation discussed several new drugs used in the treatment of rheumatoid arthritis. Although these drugs appear to be relatively safe and effective in the short-to-intermediate term, their long-term efficacy and toxicity remain to be verified in the treatment of rheumatoid arthritis.
作者 施安国
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第2期92-95,共4页 Chinese Journal of New Drugs
关键词 类风湿关节炎 来氟米特 依那西普 英利昔单抗 ADALIMUMAB ANAKINRA rheumatoid arthritis leflunomide etanercept infliximab adalimumab anakinra
  • 相关文献

参考文献15

  • 1CHOY EH, PANAYI GS. Cytokin pathways and joint inflammation in rheumatoid arthritis [J]. N Engl J Med, 2001,344 ( 12 ) :907 -916.
  • 2BURGER D, BEGUE-PASTOR N, BENAVENT S, et al, The active metabolite of leflunomide, A771726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes[J]. Rheumatology, 2003, 42(2) :89 -96.
  • 3BEAMAN JM, IIACKETT LP, LUXTON G, et al. Effect of hemodialysis on leflunomide plasma concentrations[J]. Ann Pharmacother, 2002, 36(1) :75 -77.
  • 4PEREZ-RUIZ F, NOLLA JM. Influence of Leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis[J]. J Clin Rheumatol, 2003, 9 (3) :215 - 218.
  • 5KREMER JM, GENOVESE MC, CANNON GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthrlltis despite stable doses of methotrexate: a randomized,double-blind, placebo-controlled trial [ J ]. Ann Intern Med,2002,137(6) :726 -733.
  • 6MARCHESONI A, ARREGHINI M, PANNI B, et al. Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab[J]. Rheumatology,2003, 42(4) :193 - 194.
  • 7LEE H, KIMKO HC, ROGGE M, et al. Population pharmacokinetics and pharmacodynamics modeling of etanercept using logistic regression analysis[ J]. Clin Pharmacol Ther, 2003, 73 (3) :348 -365.
  • 8KEYSTONE EC, SCHIFF MH, KREMER JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized,double-blind, placebo-controlled trial [ J ]. Arthritis Rheum,2004, 50(2) :353 -363.
  • 9LIPSKY PE, VAN DER HEIJDE DMFM, ST CLAIR EW, et al.Infliximab and methotrexate in the treatment of rheumatoid arthritis[J]. N Engl J Med, 2000, 343(23) :1594 -1602.
  • 10WEINBLATT ME, KEYSTONE EC, FURST DDE, et al. Adalimumab, a fully human anti-tumor necrosos factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial[J].Arthritis Rheum, 2003, 48( 1 ) :35 -45.

同被引文献60

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部